Rate limiting dugs and heparin in the management of atrial fibrillation
| All patients (n=1138) | Patients with no history of previous AF (n=883) | Patients with history of paroxysmal AF (n=117) | Patients with history of chronic AF (n=138) | |
|---|---|---|---|---|
| Data are presented as actual patient numbers with percentages. | ||||
| *p < 0.01, †p < 0.05 v patients with no history of previous AF. | ||||
| AF, atrial fibrillation. | ||||
| Digitalis | 558 (49%) | 422 (48%) | 60 (51%) | 76 (55%) |
| Diltiazem | 146 (13%) | 117 (13%) | 18 (15%) | 11 (8%) |
| Verapamil | 78 (7%) | 51 (6%) | 16 (14%)* | 11 (8%) |
| Diltiazem and/or verapamil | 207 (18%) | 157 (18%) | 30 (26%)† | 20 (14%) |
| Metoprolol | 238 (21%) | 194 (22%) | 27 (23%) | 17 (12%)† |
| Atenolol | 170 (15%) | 137 (16%) | 18 (15%) | 15 (11%) |
| Esmolol | 13 (1%) | 11 (1%) | 1 (<1%) | 1 (<1%) |
| Other β blocker | 111 (10%) | 84 (10%) | 14 (12%) | 13 (9%) |
| Any β blocker | 329 (29%) | 262 (30%) | 39 (33%) | 28 (20%)† |
| Heparin | 552 (49%) | 444 (50%) | 58 (50%) | 50 (36%)* |